#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	8358	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2981	666.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	2117	2117	T	1097	T,G,A,C	972,4,3,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	8358	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2981	666.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1851	1851	C	1029	C,G,A	912,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	8358	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2981	666.1	0	HET	.	.	.	C411T,G,A	.	411	411	C	1078	1078	C	942	C,T,G,A	660,182,5,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13460	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4174	760.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	2095	2095	A	990	A,T	899,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13460	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4174	760.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2729	2729	C	1003	C,G,T	903,5,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13460	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4174	760.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2803	2803	A	966	A,C	853,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13460	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4174	760.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3355	3355	C	882	C,A,T	782,3,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	784	folP	855	855	100.0	folP.l6.c17.ctg.1	1966	92.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1317	1319	AGC	100;100;100	A,G;G;C	86,1;88;85	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1888	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	4115	110.6	1	SNP	p	S91F	1	.	.	271	273	TTC	955	957	TTC	120;122;122	T;T,C;C	106;104,1;111	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1888	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	4115	110.6	1	SNP	p	G95N	0	.	.	283	285	GGC	967	969	GGC	127;127;127	G;G,C;C,A	115;115,1;108,2	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1888	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	4115	110.6	1	SNP	p	D95G	1	.	.	283	285	GGC	967	969	GGC	127;127;127	G;G,C;C,A	115;115,1;108,2	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	604	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1652	87.5	1	SNP	p	G45D	0	.	.	133	135	GGC	795	797	GGC	166;166;167	G;G;C	143;138;146	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	430	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1648	62.5	0	.	n	.	0	A197.	DEL	197	197	A	893	893	A	170	A,C	148,1	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1584	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3442	111.0	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1700	1702	GTC	138;137;137	G;T;C	132;128;132	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1584	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3442	111.0	1	SNP	p	D86N	0	.	.	256	258	GAC	806	808	GAC	100;100;102	G;A,C;C	73;64,3;81	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1584	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3442	111.0	1	SNP	p	R87I	0	.	.	259	261	CGT	809	811	CGT	102;102;105	C,T;G;T,G	87,1;69;87,2	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1584	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3442	111.0	1	SNP	p	R87W	0	.	.	259	261	CGT	809	811	CGT	102;102;105	C,T;G;T,G	87,1;69;87,2	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1584	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3442	111.0	1	SNP	p	S87R	1	.	.	259	261	CGT	809	811	CGT	102;102;105	C,T;G;T,G	87,1;69;87,2	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1584	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3442	111.0	1	SNP	p	S88P	0	.	.	262	264	TCC	812	814	TCC	104;104;105	T,C;C,T,A;C	89,2;89,1,1;95	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1658	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3359	118.9	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1773	1775	TGC	184;184;184	T,G;G;C,G	140,2;147;149,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1658	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3359	118.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1983	1985	GGC	120;121;121	G;G;C	100;99;91	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1224	1226	GCA	162;167;168	G,C;C,G;A	147,1;143,1;147	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1227	1229	ATC	171;171;171	A;T,G,A;C	151;157,1,1;158	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1239	1241	GTG	169;169;169	G;T;G	153;153;157	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1239	1241	GTG	169;169;169	G;T;G	153;153;157	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1743	1745	ACC	104;105;103	A;C,A;C	75;84,1;88	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1797	1799	GCG	84;84;85	G;C,G;G	72;71,1;72	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1797	1799	GCG	84;84;85	G;C,G;G	72;71,1;72	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1920	1922	GGC	85;86;87	G,A;G;C,T,G	82,1;83;83,2,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1929	1931	GGC	83;82;81	G;G;C	77;70;55	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1420	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2308	137.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1947	1949	TCG	83;83;83	T,G;C;G,C	46,7;58;70,2	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2068	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3570	136.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1818	1820	CCG	179;178;178	C,G,T;C,G,T,A;G,C,T	126,4,2;145,2,1,1;123,6,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	768	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2735	67.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	1058	1058	C	53	C	39	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	888	890	GAA	154;152;153	G;A;A,C	135;133;135,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1176	1178	GAT	149;160;160	G;A,T,C;T,C	129;142,1,1;140,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1299	1301	TCA	144;142;142	T,A,G,C;C;A	126,2,1,1;129;129	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1428	1430	GTC	146;151;151	G;T,C,G;C,T	128;129,1,1;131,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1758	1760	GCA	168;167;165	G;C;A,C	155;153;150,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	1	SNP	p	G120K	1	.	.	358	360	AAG	1134	1136	AAG	162;162;162	A,C;A;G,A	143,2;144;143,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	1	SNP	p	A121D	1	.	.	361	363	GAC	1137	1139	GAC	163;160;160	G,A;A,G,T;C,A	143,1;138,2,1;141,3	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1022	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2483	98.6	1	SNP	p	D121N	0	.	.	361	363	GAC	1137	1139	GAC	163;160;160	G,A;A,G,T;C,A	143,1;138,2,1;141,3	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	4290	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5327	194.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2211	2213	AAT	251;251;251	A,C;A,T;T	231,1;231,1;231	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	590	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1884	76.3	1	SNP	p	V57M	1	.	.	169	171	ATG	985	987	ATG	173;172;174	A;T;G	148;155;156	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
